About Sangamo Therapeutics, Inc.
https://www.sangamo.comSangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.
CEO
Alexander D. Macrae Ch.B, M.B., MRCP,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 33
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:11.62M
Value:$5.03M
RENAISSANCE TECHNOLOGIES LLC
Shares:10.18M
Value:$4.41M
BLACKROCK INC.
Shares:4.7M
Value:$2.04M
Summary
Showing Top 3 of 177
About Sangamo Therapeutics, Inc.
https://www.sangamo.comSangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $581K ▼ | $36.13M ▼ | $-34.93M ▼ | -6.01K% ▼ | $-0.11 ▼ | $-33.19M ▼ |
| Q2-2025 | $18.31M ▲ | $36.16M ▲ | $-19.99M ▲ | -109.18% ▲ | $-0.08 ▲ | $-18.06M ▲ |
| Q1-2025 | $6.44M ▼ | $36.06M ▲ | $-30.6M ▼ | -475.33% ▼ | $-0.14 ▼ | $-27.7M ▼ |
| Q4-2024 | $7.55M ▼ | $33.54M ▼ | $-23.4M ▼ | -309.84% ▼ | $-0.11 ▼ | $-23.86M ▼ |
| Q3-2024 | $49.41M | $38.78M | $10.67M | 21.6% | $0.04 | $12.76M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $30.53M ▼ | $88.64M ▼ | $82.4M ▲ | $6.24M ▼ |
| Q2-2025 | $38.34M ▲ | $97.56M ▲ | $77.96M ▼ | $19.6M ▲ |
| Q1-2025 | $25.18M ▼ | $86.17M ▼ | $81.26M ▲ | $4.91M ▼ |
| Q4-2024 | $41.92M ▲ | $101.64M ▼ | $78.86M ▲ | $22.77M ▼ |
| Q3-2024 | $39.2M | $111.26M | $72.13M | $39.13M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-34.93M ▼ | $-28.5M ▼ | $-64K ▼ | $19.2M ▼ | $-7.82M ▼ | $-28.56M ▼ |
| Q2-2025 | $-19.99M ▲ | $-18.16M ▲ | $-24K ▼ | $28.61M ▲ | $13.16M ▲ | $-18.18M ▲ |
| Q1-2025 | $-30.6M ▼ | $-26.15M ▼ | $0 ▼ | $8.13M ▲ | $-16.74M ▼ | $-26.15M ▼ |
| Q4-2024 | $-23.4M ▼ | $-3.35M ▼ | $1.32M ▲ | $6.99M ▲ | $2.72M ▼ | $-3.5M ▼ |
| Q3-2024 | $10.67M | $11.76M | $233K | $-203K | $12.91M | $11.64M |
Revenue by Products
| Product | Q3-2024 | Q3-2025 | Q1-2025 | Q2-2025 |
|---|---|---|---|---|
 License | $50.00M ▲ | $0 ▼ | $10.00M ▲ | $20.00M ▲ |
 Reportable Segment | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Service | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Alexander D. Macrae Ch.B, M.B., MRCP,
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 33
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:11.62M
Value:$5.03M
RENAISSANCE TECHNOLOGIES LLC
Shares:10.18M
Value:$4.41M
BLACKROCK INC.
Shares:4.7M
Value:$2.04M
Summary
Showing Top 3 of 177